03. Eicosapentaenoic Acid: Effective as Adjunctive for TRD?

Text version

Nutraceutical Eicosapentaenoic Acid in Treatment-Resistant Depression

Persistent Challenges in Treating TRD

Today, I’m going to be discussing a paper from a group in China titled “Nutraceutical eicosapentaenoic acid (EPA) in treatment-resistant depression: Clinical and psychoneuroimmunity implications.”

Treatment-resistant depression remains a significant challenge in psychiatric practice defined by inadequate responses to at least two different antidepressant trials. Despite the range of antidepressants available particularly SSRIs, many patients experience only limited benefit and the onset of therapeutic effect is often delayed.

In fact, more than one-third of patients fail multiple regimens and ultimately meet criteria for TRD. While ketamine and esketamine offer rapid relief, their use is limited by adverse-effect concerns and potential misuse. This underscores our need for alternative or adjunctive options that are both effective and well tolerated.

EPA Shows Promise in TRD

In recent years, there has been growing interest in the potential role of omega-3 polyunsaturated fatty acids particularly eicosapentaenoic acid (EPA) in the management of TRD. A review of the literature including 12 studies, a mix of randomized controlled trials and open-label studies totaling 498 participants, suggest that EPA-predominant omega-3 formulations may offer meaningful benefits for patients with TRD. The evidence points to several mechanisms by which EPA may exert its effects including anti-inflammatory actions, neuroprotection and modulation of neurotransmitter systems.

Notably, EPA appears to influence key biological systems implicated in TRD such as:

• Inflammatory pathways
• The endocannabinoid system
• The gut-brain axis
• The production of specialized pro-resolving lipid mediators

It is also important to recognize that TRD frequently co-exists with other medical conditions such as obesity and chronic pain which can further complicate treatment.

Clinical Trial Findings

A systematic review identified studies via the GOED Clinical Study Database and PubMed, focusing on omega-3 supplementation in TRD. Although definitions of TRD varied, most required at least one failed antidepressant trial or four weeks of inadequate response. Depression outcomes in these studies were measured using validated scales such as the HDRS, MADRS and BDI.

Study quality was generally high, with low risk of bias. Across trials, EPA or EPA-predominant formulations consistently reduced depressive symptoms, while docosahexaenoic (DHA)-predominant or pure DHA supplements did not.

Effective EPA doses ranged from 1,000 to 4,000 mg per day, typically administered over 4 to 12 weeks. Some high-dose EPA regimens reported remission rates approaching 100%. By contrast, DHA alone failed to outperform placebo.

EPA Works Through Multiple Mechanisms

The potential mechanisms of EPA in TRD are multifaceted:

• Anti-inflammatory modulation: TRD is often accompanied by elevated inflammatory markers. EPA downregulates pro-inflammatory cytokines and suppresses key inflammatory pathways, which may help relieve symptoms.
• Endocannabinoid regulation: EPA serves as a precursor for endocannabinoids, restoring balance within this system, reducing inflammation, and improving mood.
• Gut-brain axis effects: Diets low in omega-3s can disrupt gut microbiota and promote depressive behavior. EPA and DHA supplementation increase beneficial bacteria that produce anti-inflammatory compounds and support neurotransmission.
• Resolution of inflammation: EPA is converted into specialized pro-resolving mediators such as resolvins that actively resolve inflammation and promote synaptic plasticity—potentially contributing to both rapid and sustained antidepressant benefits.
• Neuroprotection and neuroplasticity: By enhancing neurogenesis and improving serotonin and dopamine function, EPA may support both cognitive and emotional recovery.

Safety and Limitations

From a safety perspective, EPA supplementation is generally well tolerated in patients with TRD. Meta-analyses confirmed the safety of omega-3 supplementation in clinical trials though regular monitoring for side effects is advisable especially at higher doses.

It is important to acknowledge the limitations of the current evidence base. While the included studies were generally of high quality, the overall number of high-quality trials specifically addressing EPA in TRD remains limited. Definitions of TRD varied across studies which can make direct comparison challenging. Some studies lacked full text or were not randomized which may affect the assessment of bias.

Take-Home Message for Clinicians

In summary, EPA-predominant omega-3 formulations appear to be a promising adjunctive intervention for TRD with DHA or DHA-predominant formulations showing limited efficacy.

EPA may be particularly beneficial in cases of inflammation-associated depression and omega-3s could be considered as adjunctive therapy in patients with TRD. While these findings are encouraging, more large scale standardized clinical trials are needed to establish definitive clinical recommendations. Nonetheless, the current evidence suggests that EPA and EPA-predominant omega-3s are promising safe adjuncts for the management of treatment-resistant depression.

Abstract

Nutraceutical eicosapentaenoic acid in treatment-resistant depression: The psychoneuroimmunity and clinical implications

Jane Pei-Chen Chang; Ayesha Zafar Iqbal; Quang Le Do; Muhammad Yaseen; Suet-Kei Wu; Ikbal Andrian Malau; Halliru Zailani & Kuan-Pin Su

Treatment Resistant Depression is characterized by inadequate response to at least two adequate trials of antidepressants, highlighting the need for alternative or adjunctive strategies. Emerging evidence suggests omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid, may offer therapeutic benefits in the management of Treatment Resistant Depression. A total of twelve studies, including randomized controlled trials and open label studies, with a combined sample size of 498 participants have reported encouraging outcomes with eicosapentaenoic acid -predominant omega-3 polyunsaturated fatty acids in Treatment Resistant depression. The proposed mechanisms underlying these effects include the anti-inflammatory actions, neuroprotection, and modulation of neurotransmitter systems. This review focuses on key biological systems potentially influenced by eicosapentaenoic acid in the context of Treatment Resistant Depression, including damaged-associated molecular patterns, endocannabinoid system, gut-brain axis, and specialized pro-resolving lipid mediators. Additionally, we examine the therapeutic potential of eicosapentaenoic acid in Treatment Resistant Depression with coexisting medical conditions, such as obesity and pain.

Reference

Pei-Chen Chang. J., Zafar Iqbal. A. Le Do. Q. Yaseen. M.; Wu. S.; Malau. I.; Zailani. H. & Su, K. (2025). Nutraceutical eicosapentaenoic acid in treatment-resistant depression: The psychoneuroimmunity and clinical implications. Pharmacological Research, Volume 218, 2025, 107857, ISSN 1043-6618.